Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression

D. C. Ihde, P. A. Bunn, M. H. Cohen, N. R. Dunnick, J. L. Eddy, J. D. Minna

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Combination chemotherapy with Adriamycin and cyclophosphamide was administered to 22 men with progressive tumor following hormonal treatment for metastatic carcinoma of the prostate. Objective partial response was documented in 7 patients (32%); an additional four (18%) had stable disease for a minimum of four months, and 11 (50%) were non-responders. Patients with partial response had a median survival of 14 months and lived significantly longer than those with no response (median five months); survival of men with stable disease approximated that of partial responders. Serial utilization of multiple staging procedures during chemotherapy demonstrated that although no single test allowed identification of all patients with objective tumor response or progression, improvement in a median of five parameters could be documented in responding patients. In patients adequately studied at the time of disease progression, deterioration in a median of six tests was found. Serum acid phosphatase, radionuclide bone scan, and plasma carcinoembryonic antigen were the most sensitive procedures which detected both objective tumor response and progression. Toxicity of chemotherapy was acceptable except in patients with prior radiation therapy. Administration of Adriamycin and cyclophosphamide was associated with clinical benefit in half of the patients with hormone-resistant prostatic cancer. Tumor response and progression can best be objectively assessed if several staging procedures are serially employed during treatment.

Original languageEnglish (US)
Pages (from-to)1300-1310
Number of pages11
JournalCancer
Volume45
Issue number6
StatePublished - 1980

Fingerprint

Doxorubicin
Cyclophosphamide
Prostate
Carcinoma
Neoplasms
Therapeutics
Drug Therapy
Survival
Carcinoembryonic Antigen
Acid Phosphatase
Combination Drug Therapy
Radioisotopes
Disease Progression
Prostatic Neoplasms
Radiotherapy
Hormones
Bone and Bones
Serum

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression. / Ihde, D. C.; Bunn, P. A.; Cohen, M. H.; Dunnick, N. R.; Eddy, J. L.; Minna, J. D.

In: Cancer, Vol. 45, No. 6, 1980, p. 1300-1310.

Research output: Contribution to journalArticle

@article{0695f0e5f73643c9a81f59526b84ff4a,
title = "Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression",
abstract = "Combination chemotherapy with Adriamycin and cyclophosphamide was administered to 22 men with progressive tumor following hormonal treatment for metastatic carcinoma of the prostate. Objective partial response was documented in 7 patients (32{\%}); an additional four (18{\%}) had stable disease for a minimum of four months, and 11 (50{\%}) were non-responders. Patients with partial response had a median survival of 14 months and lived significantly longer than those with no response (median five months); survival of men with stable disease approximated that of partial responders. Serial utilization of multiple staging procedures during chemotherapy demonstrated that although no single test allowed identification of all patients with objective tumor response or progression, improvement in a median of five parameters could be documented in responding patients. In patients adequately studied at the time of disease progression, deterioration in a median of six tests was found. Serum acid phosphatase, radionuclide bone scan, and plasma carcinoembryonic antigen were the most sensitive procedures which detected both objective tumor response and progression. Toxicity of chemotherapy was acceptable except in patients with prior radiation therapy. Administration of Adriamycin and cyclophosphamide was associated with clinical benefit in half of the patients with hormone-resistant prostatic cancer. Tumor response and progression can best be objectively assessed if several staging procedures are serially employed during treatment.",
author = "Ihde, {D. C.} and Bunn, {P. A.} and Cohen, {M. H.} and Dunnick, {N. R.} and Eddy, {J. L.} and Minna, {J. D.}",
year = "1980",
language = "English (US)",
volume = "45",
pages = "1300--1310",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Effective treatment of hormonally-unresponsive metastatic carcinoma of the prostate with adriamycin and cyclophosphamide. Methods of documenting tumor response and progression

AU - Ihde, D. C.

AU - Bunn, P. A.

AU - Cohen, M. H.

AU - Dunnick, N. R.

AU - Eddy, J. L.

AU - Minna, J. D.

PY - 1980

Y1 - 1980

N2 - Combination chemotherapy with Adriamycin and cyclophosphamide was administered to 22 men with progressive tumor following hormonal treatment for metastatic carcinoma of the prostate. Objective partial response was documented in 7 patients (32%); an additional four (18%) had stable disease for a minimum of four months, and 11 (50%) were non-responders. Patients with partial response had a median survival of 14 months and lived significantly longer than those with no response (median five months); survival of men with stable disease approximated that of partial responders. Serial utilization of multiple staging procedures during chemotherapy demonstrated that although no single test allowed identification of all patients with objective tumor response or progression, improvement in a median of five parameters could be documented in responding patients. In patients adequately studied at the time of disease progression, deterioration in a median of six tests was found. Serum acid phosphatase, radionuclide bone scan, and plasma carcinoembryonic antigen were the most sensitive procedures which detected both objective tumor response and progression. Toxicity of chemotherapy was acceptable except in patients with prior radiation therapy. Administration of Adriamycin and cyclophosphamide was associated with clinical benefit in half of the patients with hormone-resistant prostatic cancer. Tumor response and progression can best be objectively assessed if several staging procedures are serially employed during treatment.

AB - Combination chemotherapy with Adriamycin and cyclophosphamide was administered to 22 men with progressive tumor following hormonal treatment for metastatic carcinoma of the prostate. Objective partial response was documented in 7 patients (32%); an additional four (18%) had stable disease for a minimum of four months, and 11 (50%) were non-responders. Patients with partial response had a median survival of 14 months and lived significantly longer than those with no response (median five months); survival of men with stable disease approximated that of partial responders. Serial utilization of multiple staging procedures during chemotherapy demonstrated that although no single test allowed identification of all patients with objective tumor response or progression, improvement in a median of five parameters could be documented in responding patients. In patients adequately studied at the time of disease progression, deterioration in a median of six tests was found. Serum acid phosphatase, radionuclide bone scan, and plasma carcinoembryonic antigen were the most sensitive procedures which detected both objective tumor response and progression. Toxicity of chemotherapy was acceptable except in patients with prior radiation therapy. Administration of Adriamycin and cyclophosphamide was associated with clinical benefit in half of the patients with hormone-resistant prostatic cancer. Tumor response and progression can best be objectively assessed if several staging procedures are serially employed during treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018841988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018841988&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1300

EP - 1310

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -